Sep 30, 2026, 6:44 PMBusiness Profiles
TOMS Shoes Seller Says Bipolar Misdiagnosis Nearly Cost Everything After $400 Million Sale
TOMS Shoes' founder says a bipolar misdiagnosis after a $400 million sale nearly cost everything, but the available MarketWatch feed offers few details.
Listen to this briefingAudio briefing
Summary
MarketWatch's September 30, 2026 headline says an unnamed person sold TOMS Shoes for $400 million, was later misdiagnosed with bipolar disorder, and says the episode nearly cost everything.
The full article could not be extracted. The only excerpt says psychiatric care often follows a loss, breakup, or career ending; it provides no seller identity, sale date or terms, loss amount, corrected diagnosis, TOMS operating impact, or next steps. No public company or investor impact can be established from the limited feed.
Positives
- $400 million is the only disclosed transaction figure for the TOMS Shoes sale.
- TOMS Shoes is specifically identified as the business sold, anchoring the account to a named company.
- The headline says the crisis almost cost everything, rather than reporting a completed total loss.
Risks & concerns
- The seller says bipolar disorder was a misdiagnosis received after the $400 million TOMS Shoes sale.
- The seller says the misdiagnosis nearly cost everything, although the financial and personal consequences are not quantified.
- The available excerpt provides no sale terms, transaction date, corrected diagnosis, or subsequent financial outcome.
- No operating impact on TOMS Shoes or consequences for public-market investors can be verified from the limited feed.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/after-i-sold-toms-shoes-for-400-million-i-was-misdiagnosed-with-bipolar-disorder-and-it-almost-cost-me-everything-4409da4c?mod=mw_rss_topstories
Read full article
